Form 4: Phathom Pharmaceuticals Director Acquires RSUs

James N. Topper, a Director and 10% owner of Phathom Pharmaceuticals, Inc., acquired 24,122 Restricted Stock Units (RSUs) on May 19, 2026.

Summary

• James N. Topper, a Director and 10% owner of Phathom Pharmaceuticals, Inc. (PHAT), acquired 24,122 Restricted Stock Units (RSUs) on May 19, 2026.
• These RSUs were granted under the Issuer's Non-Employee Director Compensation Program.
• The RSUs will vest on the first anniversary of the grant date or the next annual stockholder meeting, provided Mr. Topper continues to serve on the Board.
• Each RSU represents a contingent right to receive one share of common stock.
• Following this transaction, Mr. Topper beneficially owns a total of 6,000,449 shares of common stock, including direct and indirect holdings through various entities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard equity grant to a director, indicating continued engagement and alignment with company performance.

Positives

• Director acquisition of RSUs indicates confidence in the company's future prospects.
• The grant of RSUs aligns director compensation with long-term shareholder value.
• Mr. Topper's continued service on the Board through vesting dates suggests commitment.

Risks

• Vesting of RSUs is contingent upon continued service, implying potential departure risk.
• The value of the RSUs is tied to the performance of Phathom Pharmaceuticals' common stock.

Future Outlook

The RSUs are set to vest on the first anniversary of the grant date or the next annual stockholder meeting, contingent on the Reporting Person's continued service on the Board.

Industry Context

StockSavvy.ai notes that insider grants of equity awards like RSUs are common in the biotechnology and pharmaceutical sectors as a means to attract and retain experienced directors and executives, aligning their interests with long-term company performance and shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of RSUs by a director can be seen as a positive signal of commitment and alignment with shareholder interests.
• Employees: Standard compensation practice for non-employee directors, unlikely to have direct impact.
• Creditors: No direct impact.
• Suppliers: No direct impact.

Next Steps

• Vesting of 24,122 RSUs on the first anniversary of the grant date or the next annual stockholder meeting, subject to continued service.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, SEC Filing, Restricted Stock Units, RSUs, Director Compensation, Beneficial Ownership, Insider Transaction